bluebird bio, Inc. (BLUE) Director Mark Vachon Sells 6,000 Shares
bluebird bio, Inc. (NASDAQ:BLUE) Director Mark Vachon sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $126.82, for a total value of $760,920.00. Following the transaction, the director now owns 8,000 shares in the company, valued at $1,014,560. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of bluebird bio, Inc. (BLUE) traded up 4.39% during trading on Thursday, reaching $131.85. The company’s stock had a trading volume of 1,461,591 shares. The stock’s 50 day moving average is $105.28 and its 200 day moving average is $96.03. The firm’s market cap is $6.01 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $136.85.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the firm posted ($1.59) earnings per share. The company’s revenue was up 977.4% compared to the same quarter last year. On average, equities analysts forecast that bluebird bio, Inc. will post ($6.84) EPS for the current fiscal year.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/14/bluebird-bio-inc-blue-director-mark-vachon-sells-6000-shares.html.
Institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock worth $556,918,000 after acquiring an additional 37,742 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in bluebird bio in the first quarter worth $858,000. Winfield Associates Inc. boosted its holdings in bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after acquiring an additional 162 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in bluebird bio in the second quarter worth $3,257,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in bluebird bio in the second quarter worth $1,061,000.
A number of equities analysts have issued reports on the company. Barclays PLC assumed coverage on bluebird bio in a report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 price target on the stock. Wells Fargo & Company restated an “outperform” rating and set a $158.00 price target (up from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Wedbush restated an “outperform” rating and set a $135.00 price target (up from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Cowen and Company restated an “outperform” rating on shares of bluebird bio in a report on Thursday, August 31st. Finally, Evercore ISI assumed coverage on bluebird bio in a report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price target on the stock. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. bluebird bio presently has an average rating of “Hold” and an average target price of $107.86.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.